LEXINGTON, Mass., Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present and host one-on-one meetings at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017.
Event: The Stifel 2017 Healthcare Conference
Date: Tuesday, November 14, 2017
Time: 5:00 PM ET
Location: The Lotte New York Palace Hotel in New York City
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as topical eye drops for the treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic formulation of ADX-102 is in late-stage clinical development for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 205
MacDougall Biomedical Communications
SOURCE Aldeyra Therapeutics, Inc.